“…92 Smaller studies also support the efficacy of vPDT for CSC, including a prospective, comparative study of 10 patients with chronic CSC who had undergone a single successful treatment with half-dose vPDT; vision outcomes were significantly improved from baseline with vPDT (P=0.04), and microstructural and microcirculation changes were observed 1 month after treatment. 93 A second study retrospectively analyzed data from 32 patients (34 eyes) with CSC subgrouped by fluorescein angiography (point source leakage in FA [n=17] and diffuse dye oozing [n=16]) and reported that half-dose vPDT was effective for patients with CSC with CNV, with better results in the subgroup of patients with point source leakage, based on fewer half-dose PDT sessions (1.1 vs 1.9, respectively; P=0.006) and better final BCVA findings (logMAR, 0.1 vs 0.3; P=0.02) at year 3. 94 A different retrospective study found that vPDT, regardless of the combination of full-or half-dose verteporfin and/or full-or half-dose fluence used, significantly improved BCVA from baseline to posttreatment in patients with CSC (n=30; >1-year follow-up period; 0.5 vs 0.3, respectively; P=0.008).…”